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A retrospective, cross-sectional study was conducted to determine the frequency of human parvovirus B19 (B19V)
infected individuals, viral loads and immunity among blood donors from Argentina, in a post-epidemic outbreak
period. B19V DNA and specific IgG were tested in minimum study samples of donors attending a blood bank at
Cordoba, Argentina, in 2014. Anti-B19V IgM and viral loads were determined in B19V-positive plasma samples.
Seven of 731 samples (0.96%) resulted positive, corresponding to individuals aged 32–53 years, four of them
repeat donnors and three first-time donors. Viral loads were <103 IU/mL. None had IgM and 6/7 had IgG, one of
them at a high level (in the range of 100–200 IU/ml, and the remaining 5 at low to medium level, 5–50 IU/ml).
Thus one case was classified as acute infection (DNAþ/IgM-/IgG-) and six as potentially persistent infections
(DNAþ/IgM-/IgGþ). No coinfections with other pathogens of mandatory control in the pre-transfusion screening
were detected. Prevalence of IgG was 77.9% (279/358). This study provides the first data of B19V prevalence in
blood donors in Argentina, demonstrating high rates of acute and persistent B19V infections and high prevalence
of anti-B19V IgG in a post-epidemic period. Further research is needed to elucidate mechanisms/factors for B19V
persistence as well as follow-up of recipients in the context of haemo-surveillance programs, contributing to the
knowledge of B19V and blood transfusion safety.1. Introduction
Human parvovirus B19 (B19V, Erythroparvovirus primate 1 [1])
infection is associated with manifestations that vary depending on the
host immunological and hematological status, but many infected subjects
are asymptomatic or have mild, nonspecific symptoms. The virus tropism
for erythroid progenitor cells, the high virus titer during the acute phase
of the infection (usually 106–107 IU/ml B19V or higher) and the death of
infected cells after the viral cycle is complete [2, 3, 4, 5] can lead to an
acute cessation of red blood-cells production causing clinical conditions
related to anemia, which can range from moderate to severe, even
life-threatening [5, 6]. B19V is transmitted mainly by respiratory secre-
tions and is mostly a childhood infection [6]. It can also be transmitted by
transfusion, since there is no specific questionnaire to identify or suspect
an infection in asymptomatic blood donors that could carry the virus [7].. Adamo).
m 22 April 2020; Accepted 23 A
is an open access article under tIn addition, B19V particle is extremely small and lacks an envelope, for
which it is an agent difficult to eliminate by conventional methods
(detergent, extreme pH, heat, filtration) [8]. Transmission, seroconver-
sion, symptomatic and asymptomatic infections have been documented
in patients treated with different blood products obtained from plasma
and platelet concentrates from apparently healthy donors [9, 10, 11, 12,
13, 14].
B19V is considered a potential contaminant of blood transfusion
products, since virus clearance studies have indicated that solvent
detergent-treated plasma lots containing >107 IU/ml B19V DNA can
transmit the virus to patients and seronegative volunteers [15]. On the
other hand, in some individuals, B19V may persist and the viral genome
remain detectable during many months at low (<103 IU/ml) or high ti-
ters (>104 IU/ml) [7]. Consequently, some blood donors can continue
donating while carrying the virus (and potentially infectious virions) inpril 2020
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blood recipients should be surveyed.
B19V DNA prevalence varying from 0.2 to 1.9% has been reported
among blood donors, and the concentrations determined are frequently
<104 viral genome UI/ml [18, 19]. However, individuals with higher
viral loads have also been detected [2, 19, 20, 21, 22, 23]. Thus, moni-
toring and characterizing the local B19V circulation can contribute to
undertaking measures for safe use of blood. In Argentina, B19V epide-
miology in blood banks is unknown and the screening of this agent is not
routinely performed. Therefore, we aimed to determine the frequency of
B19V DNA detection and the seroprevalence of B19V among local blood
donors.
2. Methods
2.1. General design and ethical considerations
A retrospective, observational, cross-sectional study was accom-
plished, analyzing a randomly selected study sample of blood donors.
The assays were performed in one plasma sample per individual (an
aliquot of the blood collected at time of donation, obtained to perform
pre-transfusion screening).
A minimum sample size was estimated to study B19V DNA prevalence
using PCR. All PCR-positive samples were subsequently subjected to
quantitative PCR and specific IgM and IgG testing to identify acute and
persistent infections in the study population. Taking into account that all
the individuals in the study group were asymptomatic, the following
combination of immunological parameters were considered: I. DNA-
positive/IgG-negative and IgM-positive or negative accounting for
ongoing acute infection; II. DNA-positive/IgG-positive/IgM-positive,
recent acute infection; III. DNA-positive/IgG-positive/IgM-negative was
interpreted as long-term infection or potentially persistent infection.
Presence of specific IgG was also determined in a minimum study
sample to estimate the seroprevalence of B19V among blood donors.
This study was performed in accordance with the principles of the
Declaration of Helsinki and its supplements and was approved by the
Ethics Committee of Hospital Rawson, Cordoba, Argentina (05082015).
2.2. Study sample
The study population included men and women aged 18–65 years
who attended Fundacion Banco Central de Sangre (FBCS) at Cordoba,
Argentina, between July 1 and December 31, 2014. This period was
selected for being a post-epidemic year, since during the previous year
(2013) an epidemic outbreak of B19V had occurred. Considering 8,400
average donors attending FBCS in a 6-month period, a 95% confidence
level, 5% error, and 10% expected loss, the maximized minimum study
sample required was 408. For seroprevalence, the estimated IgG fre-
quency was 70% [24] and the minimum sample size was 345.
2.3. Specimen collection, transport, processing, and storage
Individual plasma samples were randomly recovered from cryopres-
ervation (-70 C) at the blood bank and transported in biological secure
packaging with ice to the Institute of Virology, where nucleic acid were
extracted and then kept at -20 C until testing. Different aliquots of each
plasma sample were also conserved at -20 C to perform serological as-
says and further independent DNA extraction and quantification.
2.4. B19V detection
Nucleic acids were extracted from 200 μL aliquots of plasma using
guanidine thiocyanate lysis buffer and precipitation with silica [24, 25].
B19V DNA was determined in two independent repetitions by PCR, using
2-μl DNA extract in TE buffer with primers
50CACTATGAAAACTGGGCAATAAAC and 50AATGATTCTCCT2
GAACTGGTCC. The target is a 242-nucleotide NS1 fragment (2035–2276
on GenBank NC_000883.2), which was amplified at an annealing tem-
perature set at 55 C (35 rounds) [25]. The reaction contained 5%DMSO,
2.5 mM MgCl2, 0.8 mM nucleotide mixture, 0.2 μM each primer, and
0.02 U/μl Taq DNA polymerase in the provided buffer (Invitrogen). PCR
products were visualized by electrophoresis in silver-stained 10% poly-
acrylamide gels [24, 25]. The technique was validated previously, using
different panels of serum samples, such as 26 known B19V-positive
specimens (by a nested PCR technique) [24] of which 25 were also
positive with protocol used in the present study, and 35 known
B19V-negative samples (25 random serum specimens and 10 serum with
confirmed post-vaccine measles/rubella after MMR inoculation), all of
which resulted negative, accounting for 96,2% sensitivity and 100%
specificity.2.5. B19V DNA quantification
After DNA extraction with commercially available columns following
the instructions of the manufacturer (Qiagen), B19V DNA in samples
identified as positive in the screening assay was tested by a quantitative
real time PCR (qPCR). The procedure used a set of primers targeting a
fragment of NS1 region from nucleotide 2082 through 2274 on GenBank
AF162273, as described elsewere [26] and, as a reference, the interna-
tional standard WHO/NIBSC UK EN63QG 1st International Standard
2000 Parvovirus B19 DNA 500,000 IU/ml (code 99/800). The qPCR
assay was performed with TaqMan probes essentially as cited [26]. A
linear range of quantification was established between 1  103 and 2 
106 IU/ml of B19V DNA (results expressed IU as recommended [27]) in
ABI PRISM 7500 (Applied Biosystems) equipment. The sensitivity (95%
detection limit) of this qPCR assay was approximately 100 IU/ml. Each
sample was tested in triplicate.2.6. Serology
Ridascreen Parvovirus B19 IgG and IgM (R-Biopharm) ELISA tests for
quantitative analysis of specific antibodies were used following the
manufacturer's instructions.2.7. Data analysis
Donor demographic data were obtained from donor cards. The results
were described using frequencies, mean and standard deviation. Fre-
quencies are described with odds ratio (OR) values and 95% confidence
interval (95%CI). Significant differences were identified using Chi2 and
Fisher's exact tests (α < 0.05) when appropriate.
3. Results
3.1. Characteristics of the study population
Plasma samples from 731 donors were assayed by PCR. The age range
of donors was 16–68 years (mean 34.6  10.5, 95%CI: 33.8–35.4); 599
(82%) were <45 years old (estimated population odds 4.5, 95%CI
3.6–5.5) and 419 (57%) were male (estimated population odds 1.3, 95%
CI 1.2–1.6). The sampling was distributed homogeneously through the
entire study period (Figure 1).
In order to determine the seroprevalence (specific IgG), a subgroup of
358 plasma samples (randomly taken from the previous group) was
analyzed by ELISA. They corresponded to blood donations between
epidemiological weeks 25 and 51 of year 2014 (Figure 1) and the donor
age range was 17–64 years (mean 35.0  10.9, 95%CI 33.9–36.1); 289
(81%) were young adults (<45 years old, estimated population odds 4.2,
95%CI 3.2–5.4), and 192 (54%) were male (estimated population odds
1.2, 95%CI 0.9–1.4).
Figure 1. Number of plasma samples included per epidemiological week range for DNA (PCR) and IgG (serology) tests.
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persistent infections
B19V DNA was detected in seven of the 731 samples (0.96%, 95%CI
0.46–1.96%). All of them also had detectable viral DNA by qPCR, but
concentrations under the limit of quantification. In addition, none had
detectable anti-B19V IgM, while 6/7 were anti-B19V IgG-positive (of
them, only one had high level IgG, in the range of 100–200 IU/ml,
Table 1). Therefore, one donor had an ongoing acute infection and the
other six were classified as long-term or potentially persistent infections
(Table 1). The estimated rates of acute and long-term/persistent in-
fections were 1.4 and 8.2 per 1000 donors, respectively. As shown in
Table 1, given that none of these seven donors presented any co-infection
with other pathogen of mandatory control in the pre-transfusion
screening, the corresponding blood components were used for trans-
fusion/production of blood derivatives.3.3. Seroprevalence of B19V
Among 358 samples, 55 (15.4%) were anti-B19 IgG-negative, 279/
358 (77.9%) were positive and 24/358 (6.7%) indeterminate. In the
subgroup of IgG-positive individuals, 151 (54.1%) were male (estimated
population odds 1.2, 95%CI 0.9–1.5) without statistically significantTable 1. Demographic and immunological features of B19V DNA-positive blood don




IgM Type of B19V infection Pre-
79 F 43 NEG ˂3.0 NEG I NEG
93 F 32 POS 30.1–50.0 NEG III NEG
101 M 50 POS 5.1–10.0 NEG III NEG
166 M 39 POS 10.1–30.0 NEG III NEG
353 M 53 POS 100.0–200.0 NEG III NEG
536 M 37 POS 30.1–50.0 NEG III NEG
625 F 41 POS 30.1–50.0 NEG III NEG
1 Pathogens included in pre-transfusion screening tests of local blood banks: Hepati
and Brucella spp. NEG: negative; POS: positive. I. ongoing acute infection; III. long-te
3
differences compared with positive women frequency (p¼ 0.036). There
were no differences in the distribution of IgG-positive results according
to age groups (p ¼ 0.9) nor regarding epidemiological week ranges (p ¼
0.5), but the proportion of indeterminate results was significantly higher
in older donors (p < 0.0001, OR 4.0, 95%CI 1.7–9.4), as shown in
Figure 2.
4. Discussion
We demonstrate B19V infection by viral-DNA detection in 0.96%
blood donors from Argentina, using a representative sample. Analogous
frequency have been documented in Brazil (1.1%) [21], Chile (0.8%)
[28], United Kingdom (0.9%) and Ghana (1.3%) [29], South Africa
(0.9%) [19] and the United States (0.9%) [30]. At global level, the
detection rate seems more variable: while some European countries have
reported the lowest prevalence (The Netherlands, 0.06% [31] and
Belgium, 0.16% [32]), the frequency depends on the series studied [18,
21, 22, 23]. Part of the differences can be assumed to be due to the
primers, since the genetic diversity influences the detection of infection
especially when nucleic acid based techniques are used [26, 33, 34]. But
mainly the type of study and sampling and the natural variation in the
circulation of B19V can be influencing the results. Being an
endemic-epidemic infection, B19V incidence is shaped by springors.
transfusion screening1 Type of donor Destiny of blood components
Repeat First-time
x Plasma: manufacturing of blood products.
Erythrocytes and platelets: transfusion.
x Donation interrupted due to bad tolerance.
x Plasma: manufacturing of blood products.
Erythrocytes and platelets: transfusion.
x Plasma: manufacturing of blood products.
Erythrocytes: transfusion.
x Erythrocytes and platelets: transfusion.
x Plasma: manufacturing of blood products.
Erythrocytes and platelets: transfusion.
x Erythrocytes and plasma: transfusion.
tis B virus, Hepatitis C virus, HIV, HTLV, Trypanosoma cruzi, Treponema pallidum,
rm infection or potentially persistent infection.
Figure 2. A. Age-range distribution of samples tested for anti-B19V-IgG. B. Age-range distribution of results.
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records in our country indicate epidemic outbreaks in the years 2007 and
2013 [24,38]. As 2014 was a post-epidemic year and B19V persistence in
blood for up to two years has been confirmed [3], these factors can
explain the high seroprevalence and viral DNA frequency in our study
compared to others.
DNA-positive individuals were 32–53 years. This contrasts with the
report from Ke et al. [39], where 21 of 23 positive donors were<35 years
old. A high frequency of the virus in older donors might seem striking.
However, persistent infections for long periods of time, decades and
possibly life-long, have been reported [40, 41]. In line with this, in our
series only one individual had ongoing acute infection while the
remaining six had long-term/potentially persistent infections (all of them
but one with low/medium levels of IgG). Less plausibly, the occurrence of
asymptomatic re-infections could also be considered, although re-
infections are rarely described events that have been confirmed in spe-
cific cases [42].4
B19V was detected equally in first-time and repeat donors, which is
sound given its transmission mainly through the respiratory tract (any
type of donor would have a similar risk of acquiring the infection). In
contrast, a higher prevalence of sexually transmitted and parenteral
pathogens (HIV,Hepatitis B virus, Hepatitis C virus) has been demonstrated
in first-time donors compared to repeat donors [43]. On the other hand,
no coinfection with HIV, HBV, HCV,Human T Lymphotropic Virus, Brucella
spp, Trypanosoma cruzi, or Treponema pallidum was detected in
B19V-positive cases. Therefore, blood components from these in-
dividuals were considered suitable and used for transfusion or produc-
tion of blood derivatives. This implies that recipient patients were
exposed to a potential risk of infection through transfusion, particularly
concerning direct blood transfusion.
Prevalence of specific IgG determined in a representative sample was
78%, which is higher than the local prevalence in asymptomatic controls
in 2007 and 2012 [24,38] and the prevalence in Chile (55%), Brazil
(60%), Australia and England (60%) [29, 44, 45, 46]. Some attribute a
M.P. Adamo et al. Heliyon 6 (2020) e03869higher prevalence in developing countries to widespread circulation and
greater transmission of the virus in insufficient conditions of hygiene and
bioprotection [21]. However a seroprevalence rate of nearly 100% in
developed countries has also been reported [47], thus the differences
observed can be linked to the variability in the circulation of the virus, as
considered above. The local 2013 epidemic outbreak supports the high
percentage of immune individuals in our 2014 epidemiological scenario.
As expected, anti-B19V IgG prevalence was not different between
men and women [36, 44]. Regarding age distribution, the frequency of
IgG-positive individuals was high and also not significantly different
between age subgroups (76–79%). However, the frequency of individuals
with an indeterminate result of IgG test increased significantly with age
(p < 0.0001). This could indicate a decay of detectable levels of circu-
lating antibodies in older adults long time after the primary infection, as
observed by Candotti et al. [29]. In addition, given the possibility of
vanishing specific immunity, we could in fact hypothesize about the
possible occurrence of B19V reinfections in adults, which has been sug-
gested by others [42, 48]. In this matter, further research on
B19V-specific long-time immunity is required, since populations are
increasingly long-lived accompanied by increasing probabilities of co-
morbidity. Consequently, older adults could be a risk-group of reinfec-
tion, both acquired in the community and by transfusion.
Among the seven B19V-positive individuals, one had no detectable
specific antibodies and the rest had IgG (not IgM), which can be inter-
preted as one ongoing acute infection and six long-term or potential
persistent infections. Thereby, local rates of acute and long-term/
persistent infections found were high (1.4 and 8.2 per 1,000 donors,
respectively). Viremic donors had B19V DNA under the limit of quanti-
fication (1  103 IU/ml). Unless it is a very early stage of infection, low
viral load detected in donors having ongoing acute infections might not
seem in agreement with what could be expected for this stage of infection
(this applies for the one case classified as acute infection). In this regard,
underestimation of viral load due to B19V genome polymorphisms
leading to mismatches in primer binding regions is possible [26, 49].
Determination of viral loads should be achieved with a different molec-
ular target assay, but currently, there is not any other available in
Argentina. Moreover, the study of blood recipients should be considered
in future haemo-surveillance programs in regional blood banks.
Direct transfusion of B19V-containing blood and blood components
can infect a susceptible receptor. In this situation, transfusion trans-
mission is associated to risk of anemia, particularly in vulnerable re-
cipients (non-immune pregnant women and immunosuppressed/
transplant patients) in whom different moderate to severe diseases can
occur after B19V-induced depletion of erythrocyte precursors [50, 51,
52, 53]. Even when blood units from B19V viremic donors from our study
might have been used for transfusion, reception of more than one blood
unit dilute the virus and also passively immunize with neutralizing an-
tibodies. In this situation the risk of B19V transfusion transmission is low,
mainly due to the high IgG frequency. However, it should be reminded
that is a variable scenario (specific of post-epidemic periods), and both
the rate of DNA and specific IgG can fluctuate yearly.
For pooled-plasma products, FDA recommends B19V nucleic acid
testing to identify and prevent the use of plasma units containing B19V
DNA. No B19V transmission from pooled-plasma products has been
documented when less than 104 IU/ml B19V DNA are present in an
infused product, thus the proposed limit of 104 IU/ml for the production
of plasma pools destined for all plasma derivatives. In contrast, measures
to avoid potential B19V transmission by single donation blood products
have not been established so far in many countries, although the first
cases of transfusion-transmitted B19V infection were reported in the 90s
[7]. Since after acute infection B19V DNA can remain detectable in blood
for months to years [3], in a repeat-blood donor population this could
mean that multiple consecutive B19V DNA-positive donations can be
taken from a single donor. In addition, in our series all viremic donors
had undetectable IgM, thus strategies to avoid transfusion-transmitted
B19V cannot be based on serological screening (anti-B19V IgM is5
undetectable very early in the infection and in persistent infections).
Taking this into account, the molecular screening of blood seems to be
the most efficient method to avoid B19V.
In conclusion, this study demonstrates the occurrence of high rates of
acute and long-term or persistent B19V infections, as well as a high
prevalence of anti-B19V IgG, among blood donors in a post-epidemic
period. It also provides the first data on the prevalence of B19V in this
population in Argentina. Further research is needed to elucidate the
mechanisms and factors influencing B19V persistent infection, as well as
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